Marie Foegh

Marie brings thirty years of experience in the pharmaceutical and biotechnology industries to our senior management team, and has a strong track record leading successful clinical development of therapeutics, including regulatory and medical affairs.

She leads clinical development of our current precision medicine oncology pipeline, including our lead assets 2X-121, Dovitinib, and LiPlaCis™.

She previously led the successful development and regulatory approval of more than 10 novel drug products in the U.S. and U.K., within oncology, endocrinology and cardiology. Marie has fluency in regulatory interactions with the FDA and EMEA, including INDs, NDAs, IDEs (for predictive biomarkers and/or companion diagnostics), and product issues.

She also manages interactions with the oncology key opinion leaders that sit on our Scientific Advisory Board.

She holds both Medical Doctorate (M.D.) and Doctorate of Science (Dr.Sc.) degrees, and is a member of the American College of Physicians (ACP), American Medical Association (AMA). American Society of Clinical Oncology, and the American College of Obstetricians and Gynecologists (ACOG).